Antiemetic therapy in managed care oncology: roundtable discussion.
Few diagnoses are feared more by patients than cancer. In addition to the life-threatening nature of many cancers, the spectre of very difficult the treatment provides patients with little or no level of comfort. However, recent advances in the treatment of the side effects of cancer chemotherapy are helping to change these attitudes. On April 4, 1996, a panel of experts was convened to discuss these issues and how they affect MCOs.
Gerbino
P P
PP
Goldsmith
M
M
Kenney
J T
JT
Lindley
C
C
Nolte
J
J
Quan
W
W
Reich
P R
PR
D000932:Antiemetics / Q000191:economics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000191:economics; D017829:Granisetron / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008329:Managed Care Programs; D006278:Medicare; D017294:Ondansetron / Q000191:economics / Q000627:therapeutic use; D012052:Reimbursement, Incentive; D012702:Serotonin Antagonists / Q000191:economics / Q000627:therapeutic use; D014481:United States; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy / Q000191:economics